| Structure of cyclin-dependent kinase 2 (CDK2) in complex with the specific and potent inhibitor CVT-313 SR Talapati, V Nataraj, M Pothuganti, S Gore, M Ramachandra, T Antony, ... Acta Crystallographica Section F: Structural Biology Communications 76 (8 …, 2020 | 7 | 2020 |
| Potent and selective inhibition of CDK7 by novel covalent inhibitors LK Satyam, R Poddutoori, S Mukherjee, S Marappan, S Gopinath, ... Cancer Research 76 (14_Supplement), 3070-3070, 2016 | 4 | 2016 |
| Preclinical profile of novel and potent small molecule inhibitors of PARG S Patra, M Pothuganti, G Kummari, V Sankeshi, J Kapaka, N Karche, ... Cancer Research 84 (6_Supplement), 7112-7112, 2024 | | 2024 |
| Preclinical profile of novel and potent small molecule inhibitors of KIF18A inhibitors in chromosomally unstable solid tumor lines S Petra, M Pothuganti, N Karche, G Gudade, V Sankeshi, G Kummari, ... MOLECULAR CANCER THERAPEUTICS 22 (12), 2023 | | 2023 |
| Abstract A024: Preclinical profile of novel and potent small molecule inhibitors of KIF18A inhibitors in chromosomally unstable solid tumor lines S Patra, M Pothuganti, N Karche, G Gudade, V Sankeshi, G Kummari, ... Molecular Cancer Therapeutics 22 (12_Supplement), A024-A024, 2023 | | 2023 |
| Abstract A099: Best in class, potent, SOS1 inhibitors demonstrate single agent activity in preclinical models of KRAS driven tumors B Lakhavath, M Pothuganti, G Kummari, H Pathange, R Sekar, ... Molecular Cancer Therapeutics 22 (12_Supplement), A099-A099, 2023 | | 2023 |
| 35P SAT-122: A potential first-in-class, potent, small-molecule disruptor of RAD51-BRCA2, attenuates RAD51 foci formation and tumor progression in preclinical models S Patra, M Pothuganti, V Sankeshi, H Pathange, K Soumyajit, ... Annals of Oncology 34, S197, 2023 | | 2023 |
| Structural and binding studies of cyclin‐dependent kinase 2 with NU6140 inhibitor SR Talapati, M Goyal, V Nataraj, M Pothuganti, S Gore, M Ramachandra, ... Chemical Biology & Drug Design 98 (5), 857-868, 2021 | | 2021 |
| Discovery and preclinical evaluation of a novel covalent inhibitor of FABP5 for cancer therapy D Chikkanna, LK Satyam, SK Pnaigrahi, V Khairnar, M Pothuganti, ... Cancer Research 81 (13_Supplement), 1266-1266, 2021 | | 2021 |
| Anti-tumor efficacy of SMARCA degraders in pre-clinical models of cancer LK Satyam, S Sasmal, MK Pothuganti, S MR, A Ettam, S Nunna, ... Cancer Research 79 (13_Supplement), 3844-3844, 2019 | | 2019 |
| In vivo anti-tumor efficacy with a dual degrader of SMARCA2 and SMARCA4 G Daginakatte, S Sasmal, LK Satyam, MK Pothuganti, A Ettam, S Nunna, ... EUROPEAN JOURNAL OF CANCER 103, E134-E134, 2018 | | 2018 |
| Abstract LB-258: Identification of SMARCA2/4 degraders for the treatment of SMARCA4-mutant and other cancers S Sasmal, LK Satyam, MK Pothuganti, A Ettam, S Nunna, MA Shareef, ... Cancer Research 78 (13_Supplement), LB-258-LB-258, 2018 | | 2018 |
| Abstract B164: Identification of a novel highly selective and orally bioavailable preclinical candidate for CDK7 covalent inhibition R Poddutoori, L Khare Satyam, S Mukherjee, S Marappan, S Gopinath, ... Molecular Cancer Therapeutics 17 (1_Supplement), B164-B164, 2018 | | 2018 |
| Abstract LB-317: Identification of a novel preclinical candidate for CDK7 inhibition LK Satyam, R Poddutoori, S Mukherjee, S Marappan, S Gopinath, ... Cancer Research 77 (13_Supplement), LB-317-LB-317, 2017 | | 2017 |
| Potent small molecule compounds that selectively inhibit proliferation of ABC-DLBCL cell lines LK Satyam, D Chikkanna, V Khairnar, M Pothuganti, S Panigrahi, ... Cancer Research 77 (13_Supplement), 5108-5108, 2017 | | 2017 |
| Abstract C190: Potent and selective inhibition of CDK7 by novel covalent inhibitors R Poddutoori, LK Satyam, G Daginakatte, S Mukherjee, S Marappan, ... Molecular Cancer Therapeutics 14 (12_Supplement_2), C190-C190, 2015 | | 2015 |
